Australian Clinical Labs Stock Price

ACL Community Fair Values

• AN

  

  AnalystHighTarget

  Consensus Narrative from 9 Analysts

  Ageing Demographics And Personalised Medicine Will Boost Diagnostic Demand

  Key Takeaways Unique technology, operational discipline, and first-mover test exclusivity position ACL for superior margin expansion and revenue acceleration compared to competitors. Ageing population, chronic disease trends, and strategic capital deployment underpin strong long-term growth, market share gains, and robust shareholder returns.

  AU$4.76

  FV

  43.0% undervalued intrinsic discount

  5.61%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  0users have followed this narrative

  10 days ago author updated this narrative
• AN

  

  AnalystConsensusTarget

  Consensus Narrative from 9 Analysts

  AI And New Genetic Tests Will Drive Future Operational Improvements

  Key Takeaways Expansion into genetic molecular testing and operational efficiency initiatives are set to bolster revenue growth and enhance net margins. Strategic acquisitions domestically and internationally offer accelerated growth potential by expanding market share and leveraging synergies.

  AU$3.74

  FV

  27.5% undervalued intrinsic discount

  4.72%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  17users have followed this narrative

  3 days ago author updated this narrative
• AN

  

  AnalystLowTarget

  Consensus Narrative from 9 Analysts

  Regulatory Shifts And Inflation Will Strain Margins With Automation Gains

  Key Takeaways Uncertainty in sustainable revenue recovery and exposure to government policy changes present challenges, despite long-term growth trends and innovation in high-value testing. Efficiency gains and new high-margin tests could drive margins, but labor cost pressures and competitive industry shifts may limit overall earnings growth.

  AU$3.15

  FV

  14.0% undervalued intrinsic discount

  5.61%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  0users have followed this narrative

  10 days ago author updated this narrative